AsemconnectVietnam - This is an invention of the United States, through the cooperation between the United States Department of Agriculture (USDA) and the Ministry of Agriculture and Rural Development (now the Ministry of Agriculture and Environment), transferred to Dabaco Group (DBC) for production and commercial operation.

On March 29, at Khac Niem Industrial Cluster (Bac Ninh City), Dabaco Vietnam Group Joint Stock Company held the inauguration ceremony of the Dacovet Vaccine Factory and announced the commercialization of the Dacovac-ASF2 vaccine to prevent African swine fever (ASF).
The Dacovac-ASF2 vaccine is the result of cooperation between the United States Department of Agriculture (USDA) and the Ministry of Agriculture and Rural Development of Vietnam (now the Ministry of Agriculture and Environment), transferred to Dabaco for production. This is an important step forward to help the domestic livestock industry reduce its dependence on imported vaccines.
This vaccine was licensed for commercial circulation from February 28, 2025 and is expected to help control ASF, a disease that has caused severe damage to the Vietnamese pig farming industry since 2019.
The Dacovet vaccine factory has a total investment of more than VND300 billion, a capacity of 200 million doses/year, and is the 12th vaccine factory in Vietnam. The factory is equipped with modern production lines imported from the US, Germany, and Japan, along with a highly automated system, ensuring strict quality control according to GMP-WHO standards.
Speaking at the ceremony, Deputy Minister of Agriculture and Environment Nguyen Hoang Hiep highly appreciated Dabaco Group for investing in infrastructure, building a modern veterinary vaccine factory to organize research, production, thorough evaluation and licensing of commercial circulation of Dacovac-ASF2 vaccine.
Chairman of Bac Ninh Provincial People's Committee Vuong Quoc Tuan affirmed that biotechnology is one of the pillars to promote sustainable socio-economic development of the province. The inauguration of the Dacovet Vaccine Factory is also a testament to the strong development of the domestic veterinary vaccine industry, reducing dependence on imports; at the same time, creating products with high added value and affirming our country's position on the world biotechnology map.
Sharing about Dabaco's vision for the veterinary vaccine sector, Mr. Nguyen Nhu So, Chairman of the Board of Directors of Dabaco Group, said that the global vaccine market is a competitive arena, where big names with superior resources dominate.
"To rise in the race for quality, price and distribution network, Dabaco must make many times more efforts. But I believe that, in that pressure, we find the motivation to overcome the limit, not only for Dabaco, but also for the development of the Vietnamese livestock industry," said Mr. So, adding that Dabaco is and will continue to research and develop vaccine lines for livestock and poultry to serve the livestock industry, gradually affirming Vietnam's position on the global biotechnology map.
On the morning of April 19, at the Company's headquarters in Bac Ninh City, Dabaco Group will hold the 2025 Annual General Meeting of Shareholders.
According to published documents, by the end of 2024, Dabaco recorded revenue of VND13,573.5 billion, an increase of 22.2% over the previous year; After-tax profit reached VND769.1 billion compared to the same period of VND25.01 billion, an increase of more than VND744 billion (30.7 times higher than in 2023). In which, gross profit margin improved from 10% to 14.2%.
In 2025, the company plans total revenue of VND28,759 billion; pre-tax profit of VND1,108 billion; expected after-tax profit of VND1,007 billion, an increase of 30.9% over the same period last year.
Closing the trading session on March 28, DBC shares increased by 0.68% compared to the previous session, to VND29,800/share.
On March 14, foreign fund Pyn Elite Fund (Non-ucits) sold 5 million DBC shares to reduce its ownership from more than 17 million shares (5.11% of charter capital) to more than 12 million shares (3.61% of charter capital) and is no longer a major shareholder at Dabaco.
N.Nga
Source: VITIC/Tinnhanhchungkhoan